US approves migraine spray

The new drug inhibits peptides associated with the calcitonin gene. Previous studies have shown that they play a role in migraine pain. The medicine has passed clinical trials involving more than 1000 people. Two hours after taking one dose, 24% said they had no more pain, and 40% were relieved of their most bothersome migraine symptom. However, for some participants, the pain became easier in just 15 minutes. In addition to the quick action, the relief from the medicine was also long lasting. It persisted up to several days.